Location & dates EMBL Heidelberg, Germany 5 - 7 Feb 2020 Register Now
Deadlines Registration - 7 Jan 2020 Abstract - 13 Nov 2019

Conference Overview

Despite the exciting advances in human genetics over the past decade, the fraction of the human proteome targeted by small molecules remains relatively small compared to the total number of genes linked to a disease phenotype by Mendelian inheritance or genome-wide association studies. Chemical biology is a scientific discipline that promises to apply the latest chemical approaches to interrogate complex biological systems and is, consequently, at the very heart of modern pharmacology. This conference will explore how recent advances in chemical biology are helping to expand the druggable proteome and enhance our understanding of disease biology with three major themes: 

  • illuminating the druggable genome
  • chemical interrogation of the druggable proteome
  • new engineering approaches for breaking the druggability barrier

Co-organised with industry partners of the EMBL Corporate Partnership Programme, emphasis has been put on bringing together academic and industrial scientists with interests in chemical biology, chemogenomic libraries, pharmacology, medicinal chemistry and bioinformatics who have the curiosity and courage to challenge existing thinking and explore new ways of expanding the druggable proteome for better medicines.

 

EMBL Courses and Conferences are kindly supported by our Corporate Partnership Programme

Founder partners

  • Leica logo
  • Olympus logo

Corporate partners

  • 10x Genomics_120x82
  • Becton Dickinson logo
  • Boehringer Ingelheim logo
  • Eppendorf logo
  • GSK logo
  • Milteniy Biotec_logo120
  • Sartorius
  • ThermoFisher logo

Associate partners

  • Merck logo
  • NEB_logo_120
  • Nikon logo
  • Promega logo
  • Roche logo
  • Sanofi logo